Markets
Kodiak Sciences Nearly Triples After Both Retinal Drugs Meet Primary Endpoints in the Pivotal DAYBREAK Trial
Zenkuda and tabirafusp-ted both cleared vision endpoints against aflibercept, and Kodiak says a multi-indication FDA filing is planned for the fourth quarter.
ME
By Marcus Elrod
Sep 29, 2026 · 5 min read
Shares of Kodiak Sciences (Nasdaq: KOD) closed sharply higher Monday after the clinical-stage biotechnology company said both of its lead retinal drugs met their primary endpoints in a pivotal Phase 3 trial, clearing a path to a planned multi-indication U.S. regulatory filing before year-end.
Discussion (0)
Sign in to join the discussion.
Loading comments…
ME
Marcus Elrod
Marcus tracks positioning, flows and rates. He writes CI's weekly market internals column.
Marcus Elrod writes for Corporate Insider Inc.